0001193125-12-493576.txt : 20121206 0001193125-12-493576.hdr.sgml : 20121206 20121206151834 ACCESSION NUMBER: 0001193125-12-493576 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20121206 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20121206 DATE AS OF CHANGE: 20121206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGENOMICS INC CENTRAL INDEX KEY: 0001077183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 742897368 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35756 FILM NUMBER: 121246460 BUSINESS ADDRESS: STREET 1: 1726 MEDICAL BOULEVARD, SUITE 201 STREET 2: SUITE 201 CITY: NAPLES STATE: FL ZIP: 34108 BUSINESS PHONE: 9419231949 MAIL ADDRESS: STREET 1: 1726 MEDICAL BOULEVARD, SUITE 201 STREET 2: SUITE 201 CITY: NAPLES STATE: FL ZIP: 34108 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC DATE OF NAME CHANGE: 19990120 8-K 1 d450336d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

December 6, 2012

 

 

NEOGENOMICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada   001-35756   74-2897368

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

12701 Commonwealth Drive, Suite 9, Fort Myers,

Florida

   33913
(Address of principal executive offices)   (Zip Code)

(239) 768-0600

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On December 6, 2012 the Company issued a press release to announce that they had been approved for listing on the NASDAQ Capital Market. The Company expects to commence trading on December 10, 2012 under the ticker symbol “NEO”. Prior to the listing change the Company’s common stock will continue to trade on the OTC Bulletin Board under the current ticker symbol “NGNM”.

 

Item 9.01. Financial Statements and Exhibits.

 

  (a) Not applicable

 

  (b) Not applicable

 

  (c) Not applicable

 

  (d) Exhibits.

 

99.1    NeoGenomics Announces NASDAQ Capital Market Listing

 

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NEOGENOMICS, INC.
By:  

/s/ George Cardoza

  George Cardoza
  Chief Financial Officer

Date: December 6, 2012

 

- 3 -

EX-99.1 2 d450336dex991.htm NEOGENOMICS ANNOUNCES NASDAQ CAPITAL MARKETS LISTING NeoGenomics Announces NASDAQ Capital Markets Listing

Exhibit 99.1

 

LOGO

NEOGENOMICS, INC.

PRESS RELEASE

FOR IMMEDIATE RELEASE

NeoGenomics Announces NASDAQ Capital Market Listing

Ft. Myers, Florida – December 6, 2012 – NeoGenomics, Inc. (OTC BB: NGNM), a leading provider of cancer-focused genetic testing services, announced today that its common stock has been approved for listing on the NASDAQ Capital Market.

The company expects to commence trading on the NASDAQ Capital Market on Monday, December 10, 2012 under the ticker symbol “NEO”. Prior to the listing change to NASDAQ, the company’s common stock will continue to trade on the OTC Bulletin Board under the current ticker symbol “NGNM”.

Douglas VanOort, the company’s Chairman and CEO, commented, “The transition to the NASDAQ Capital Market is a significant milestone for NeoGenomics and reflects the strong revenue and operating income growth we have achieved over the last several years. We believe this move will increase the visibility and liquidity of our shares in the market, and we are honored to join the long list of prestigious companies already traded on NASDAQ.”

In honor of the transition to NASDAQ, Douglas VanOort, Chairman and CEO, and other NeoGenomics colleagues will ring the closing bell at The NASDAQ Stock Market in Times Square in New York on Thursday, December 13th.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company’s periodic filings with the SEC.

For further information, please contact:

 

NeoGenomics, Inc.    Hawk Associates, Inc.
Steven C. Jones    Ms. Julie Marshall
Director of Investor Relations    (305) 451-1888
(239) 325-2001    neogenomics@hawkassociates.com
sjones@neogenomics.com   

 

2

GRAPHIC 3 g450336ex99pg001.jpg GRAPHIC begin 644 g450336ex99pg001.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`?P!!`P$1``(1`0,1`?_$`+T```("`@,!`0`````` M``````@)``<&"@($!0$#`0`"`@,!`0``````````````!@4'`@0(`P$0```& M`0,"`@0("`T%``````$"`P0%!@<`$0@2"2$3,2(4%4&AL<%T-1:V88&1,D(C M%SCP47'18G(S)#14M+4V)74F1A@1``$"!`0$`@0+!P,%``````$"`P`1!`4A M,1(&05$3!V$B<8$R%)&Q0E)R@K(C<[,T\*%B,Q4U-L'Q%J*#DR0E_]H`#`,! M``(1`Q$`/P#?XT01-$$31!$T01-$$?#&`H;C\WS[:^$Z1./A(&)RBA\^6.TQ59A&JJ/MC*#I-.F+?:+>_;B852P<26/;LS'`/6=/T2 M[_G;2U#9*FY6VLNJ9IH:)""I1!DI3B@A+<\M1!49?PF(6OO5-0W*DM9\U;6* M6$C"82A)4I&_C^(/2.O,+GP,O1^[E./A4`9?[PK'N!=VKC1P2A'D%*3#;* M>>7J"B55PA2I!%[.#)G$J+-2\R+0KQ"D1(N5"[@X*9^X*.S9LL.^UJ]O^TFZ M.X#X=IT"DL:/,Y5/A2&@GCH,O.J6.&`^41A.L-]=U=N;+9+*U"KO*B4IIV2E M2M60ZF/E$_K2KOW).VNT$C'*L<)`[4@J._P!:Z.F2;[H7G:UJH&>W.Q%=2S4;NNIJ M)@^]U0&DJU`F:$`D"4DS(TB0G$-VVLFXKE7N[]WF--XJV]+#6(%/3JQ`"9#2 MI6',RF29F'@%``#8/P_+JD@)`#E%TC'&.6OL$31!$T017V0,G4_&D:$G:Y=- MD"H=+&.0*#F9E%A-T@C&QQ#>>X-U#L)MBIE_2,&@)452!$I>H2S)/`2C!2PG M//AX^$H2USD[JN-<#,7<9DJV/JB\JM97-]L;+)>8S5M#@5$H[&= M?D`+_B7YT#B01\M!WMJT-@=HMX]PJA(M;"FK85R-2ZDI9D#CH)`4XKA),\N& M<5IO;NOM79+*A6O)>N.DZIQPQ9 MDJ6E!8M$;F%99BB=,B;J-5S;8&\<^4>N!*)`90(,C+K'\H$S&$-^IZ/M)VI[ M96E=VW0#>+O3:0I"05`*GJ!#"%*"0)#S.3(SPG'/-5W"[H]RJP4.W0;797/E M^RDI,P=;Q3,GP21#M^USVO.)W'6PDO64I!QF3F`DY&2?RN58HS-G49E0%#N7 M>.JW,+/?><@8QQ,:9>J.9,3%`Z16H")1Y[[D][MQ;Q:-DM:?Z;M0`I##1$UI M!P#BDI$A@/NTR3SU2G%S=ONS5BVHM-TNJA7[BP5U5@Z&R09]-)49G'VU3/*4 M;"Q2E*)MM_'T[B(_*(ZHSC/C%W"0P$<]$$31!'G2LM%P;!S*3,@RBXYHF95R M]?N4FK9%,H"(F466,4@>CP#TB/@'CH@E/"`0S1S'BX2"DY&IS$-4* M5[H)FD9[64IQ]AIT*=-20L ME(R'-1R2/$DY-EJ:O:O'OBM'VZ.R/:DV) M+AFRW).$LDLHFQ`B*)H!!8J\?BB#DXM^FNXD%14>-&2I3$N_*EBIHTA6AD'[M2T8*3,*!>6@B00)#5@08YE[I=T[_`%-P_P"'[,;6 MBY+">HZ/:;"I$`#2=,P?,K,#E%9\?.W7@*I!(W/E/EC$V8[RXE$)U!>"Y135 M-KL29$4GBB]G4L?'J[.K?**/`,#E1VX]B,4NW2H`B89K=?>;<%>E%LV%3.VZ MT)042]WUN+!FGRA*@EL:92"1JGD1"?MKM7:J=*KANQ]%77J7K!#RDI0H8DJ) M0=:IX9`'D8,[)^V=WU'3]V MJZ"YNJ.FH"$AOPZS>H)GP*T^F9QATMFX:NTMJ4^ZPNB1+2C4HJY$`E)E]8>@ MPSGCAS;0M+)%*EV!WDZ'9M2.)7'EJZ8;--09))E%!G+4S@! M`/7*V'<`J3<6S+U87I5+8=I"J0>;.IM7*2AEX@RQRG%BVZ]4=>`$J"72`=!] MI,\0.$_3*&88_P`J4?)C$SRHS:#U5`@&?1:X"UF8TQC"7I?QJNRZ(=0;=8=2 M8CZ##I3TE/E.8B9!!$QE%A[A_&&B/LC`D5AI]Y94Y:'G8U M"3CG9HZ-:NV*_EJ@59NZ9K&$4U$CD,`&$!W*(AK8I4!VH0T?94M(/H)`CS>) M#2E)EJ"21/+"!`X-<>JCG.AT;EAGAPYRSD"PA+*5.`L+5DECS&,?%3[^-;1] M.I#4A(-$04CA6*JHD84S']4O6`J&LC>=\X=4K&O+5 MK.TOE)WDMC9X[)7**CS]NP!*UR%G(`D9&\?J9:6SBLTA!0"N57(H])E"!ZQ4 MPZ+1N]/<;UV\VY4VU'5L"*8,%I+;*D-UFM25%9<>;/5>.6!].,4+1^ZVON#? M*&K3IOSM270X5N)6Y3J`4E*`V@G0D8G$"6'",O./(GDF\6:P;GD1`X<9JG:2 M3Q?(W<,N,9D%=H^(95!JX+BN869$!%,-B&0`$0,`J`KPBT)2UQV` MXUM6G]JM^+DA:/9&*JTAR"[C%*,I>,3]LMM8ISW*@2MLD3DIVH0D_ M66T!/P!GR$8#CRV/E#[`38"[BGW&ZLK"V:1MGI*E)?2#:QXB14`?AA\M6W%-! M%17N.^]).*0ZI;?KU2F/"4-9JG;!PC7\*1M4L[B9DYL<#O[+ M-%D92SQ^4/M;,%C8QC*V]>K3M@A89Y9'K%H@XEG39DP3W.J8?,5`5#]2@B8= MWN%;*.T[I?I+>VEJCTMJ2A.2=:0I0'(8X1Y;?JGJJWI4^HJ5,B9S.DRF?&4I M^,-[V_E_(7^;23)43NJ`OY;_`%MB'_N%S_V-IK=H/UC7XB/M"/*H,F%G^$_% M&.=LPO5PCPD`#MLQM7CMO_[M8]-/<43WA5CAY/RT1#;;QL[9R(4O[1A8'?AX MF5_)C;#&;:1/Q^,>0%:&P5YCD9Y*2$%#V&G,$"R:=)M#R)(N[.91\^6]@5*F M

>J@H!D%#=%I]B^X#&T6KC3[B4'=J%*'%H*0LMN3TAQI!GYOG!(GD<)15W M=OMZO='NURL2NAN9F82X%:=:1B$.*&($YA*CA\F8@#8+E)-VC'6)L)U_&&., M79BL:492G]EKN8,C14?.V=Z8[9JC1X^UWR*@:DZDRF*HNHJ=R!'1C"B)"B3= M*O=?<[M?JVKVV:FLM*"MQ*WJ=M2TMCY3DD8`#V0J1TB+ME?.6MOEPVA9$A!3.FBJBV$`VZUBZK)Q\K652`4K$GB?@P'H&'A% MD-MH0D--DA"!(#']I>G.'+UFK5NF0O MXC"6>W4`^Z.-P^&WL>=```_!<[7XC\'I'5A=T_\`,'OPFORDPM[5_MJ/2OXQ M#M-5Y#)`6\M>HTWB!,/0+VZF'\4(S#Y];5#A6-?B(^T(PJ?TZ_HGXHQ[ME_N M283V_P`E:OOK8]-7<;#>-5]3\M$0VV9FS-R^!E;0<*>`"7%))"IXZ<>6,:>X[Z;7B8!65P]BWE_4*YQ?MC.5"W4-Q)-ZK,8L+Q&R=-1,HHLG[6^ MJMB:67!>19I>8,BF==H^/+%=>64R8"<"]/0]O-3VQJ3NS:[2/Z#4)25MK+Z$ MK21@EX%+C:0#,!1`(,YX9T5>Z!6_6$VN\N+76-*)0MLLN+;)Q*DD%"U`<48B M0$L9Q9&#NXES)[5MW98*YR4K,.7^(+:58U+&?(6R8ULM8NM"DI"#.2@"9B+L?<+=G:^N%@WJU45.UDJTM52T$.(1PG*>H#BA4U` M9&4;3V'RUYV1TS6W*0RK1VEL1U&2K,3@5PS MOXC"6 M^W5]3<;?HF=OOG:M6'W3_P`P>_#:_*3"UM7^VH]*_C$.RU7D,D!=RQ_Y!B#Z M5=?]F9:V*+]6W^(G[0C"I_3K^B?BC&^V9O\`_$6%-M]_8K1MMX#_`,VL6FSN M/AO"K(EJFB4YR_EHY1";:$[,V,9:E99^T8";D-(ON+W).XH6YWG>)QKR.L\? M:\=WS$.:'%`;U"VKMV[2ZUN8@;A,?LG425D2E?`JZ:)JB1T)S'.7J%*,M-P0 MVVBC?%'[LD&779*P"3\]M/5,^$S+A'G>+:IQ9KV#6>]$`$,/:"0/X5GIX#,< M93C'LX8-KV6JRDK;)+.\X=-8#Q.1;KP]Q%R1DH@Y#`98B5SXQ-X^>=,C@7=8 MZKA82&#KZB&`!T^[>W-<+#5J?HO=%-.&2V4U#C:%CP;=P'I,L<\(0;A;J*M8 M/O!J/*9:ETS;@2>1<:.L>J`2G7-&I%1GN.N:G6/+YC7('F0Z4^7/7(GC4#R. M.K'$[KVH5TMUISK4S MT&'BE>9T.,J05`\05J"LB!"57TU$ZPJSWI3+U`Y),^J^S,9":74J2F4\"$S3 MF('LN..:G9^L4GRLXAUN:O7":=4AW65<;RF5J3FFL))*#[.+^0L&.%$'2;-) M%7=C:R13!9F*Q$GI%TOSVNFN^R>^-O1M3>KB:7N$VM::=]#*V5+,AY5ZTD`S M]IK4F]F;VLN^K-_5; M.LD)`2XVH26TY*90KGX*$P1.`>[=?U/QN^BYW^^=JU)]SS/=;A.?29_*3&YM M;^W)'$*7^Y4.RU7T,V3^Y)A/Z#:?OK8M-O<7_,:OZGY:(AML?V=OZ2OM&"6SAA#'_(/'LQC M7),2,G`2Q4U45VZA6TK"2C83'83<&^$B@LI1BH;-LTU:DNT;;2:W4)*5J`(XS+:DKGR((\8MM[EBB93C`I1LNHRU+EFC1G) MU^'Y:%41*19LFL#);'W./$4S$,Y9J8X=*#:W',F<`Z%RAL.G:WU;C*&[U;6P M*C4"%JI])G]*E\-R^!PX\8H6O4^ MMT2^O<27:D5%]B6W'DU:=;TG M(4A0Q[A7VIWCVOIZV^MO&^VRZ-M!]U*$EYMY"RI)*%*2I0T@J*2D3`.D3E$= MV_M;6U>Y+MNM3K)M=QH75*:;4M0:6T4E)`6E*@,2$A0)DK,XF&`=NL/^B\;! MWWW:YXW#T;=-SM/R@.JC[G&>['#B?N6V1^Y'A+Z#:?OK8 MM-G<7_,:OZGY:(AML_V=OZ2OM&#UTDQ/QXU@KT':X64KEEB(V=@9MFM'R\/+ MLT)"-DF3@HE6:O6;DBB*Z*@#X@8/3X^D-$$(SY"\%LV\:'MCRSP;M5I0JTH@ M=6Y8C:BRGI%FR*IYRAH.(L#&7B[C#H`)@*U<-U9%HF(^2=8!$"[5)5JIWDOJ M&O3P)4)RX'201ZI>F-"NHT5M.:77-W$$+449%*DUVNY MZ@IR,D(>.1QIB^(L,E(-$RGE7MSN*JBEQ&WW&EH=)4[H&L>7II>2XA9P^>,)SGA',/=+<5KV@OH)4V M_<,VTI#>KD>KTUMK;SE(@YX"&U]E7BQFY='*W<+Y5KV8V7.0-1+5,5P%ME)^ M6EJG@Y)1&99*'4M;Z7L;5C/.6;,L4@[>*N$XEFFJH(F6&CLQM>\+#^_-SZA=:YD)92HJFBG M.*9ZLI@)TC$Z1,DDQ?W;IV]Q\;?1_A,\^(?ANEHW^359]T,-W.\NDS+P'2$A MZA%P;7FJW)4>*G#_`-4.MVT@3ACTP)W)^`!P-(N$@_\`=U?IXV4THNA&OY=^ MLO-,&K%@W:,&"9O5$Q#G4664112(3Q/N8H#Z,.!EY#I]E*TGX"#&+J=;:DXX M@CX8`OBSR44XA4&JX4SG`IGQ3"KR#:E\C*"G(V*BG;2TJ[DQ9Y&8`W";HTHF M^?&(`.$2@"?3N02@*QK1OEGIM[U#E^VV^E5P4E/4HW"$OA24@$M_)=3A/RF? M"%.@K';"RFAN;9#$R4NIQ1(GY?S3#@J[:Z];X9E8:I8(:R0,BF55A-0,@TEH MQX0P`8!0?,E5FR@["&X`;J+OXAJJZAFIHWC3U:%-O(,E)4"".JIM#PR:!275'D$3F/29"-67D3WQN9W-JUGPGP=IRF! M:A97CF';W-Y-0;/)1)#CIX"8D?FXRCE_S>6]*H6;8["Z2 MD<)!=4$]10\5D:$)YZ2#+C`G8J[?TFUNZL9D"1K&7^1KV7>V60D6O(K`DSBZ M*(8Q7*#V8M$WD%.0MMOD7:XKN3N3D\E82$(DLH)C!(;Z[A7*\[6=IML.+L^V MPA+34J9[K+(]H)0&]3:$@:4E`GC,D#/YL;8=%:;^W6[H2S<+V7-0E4(+2>)) M)4-1QF/DS$N4;'>#NY#EA?'\G@^5QW@E@*BNNU'V5\44U2JIB<=^3K?L=];0O.XZA%OM>HJF[/K.Y$AIK M,ZQBDG"><=7O7QN0IK8T7ZHB4DD:0)2U+4)A('(01?!/$CRK0^+V7V@:3;W& M#2^I61]'0LXA5I!Q>9:3ER(U>PO6R*,J:(<2?LZP*$1,IT"HF!B;;PV\[U3[ MBO[ETI`M-,4I2D+`"B$("02!@)RG*<;]EHEV^B2P[(N`G++S&&/^O#./)UM#B"ESV%9X3GAQC5MY7\G,QX*Y,R?$CMX-;% M0^0LT9W`9KC:-/1DEAJ$D)ABV53DZ_#6%-W#4FRQC-\1>0DSKD80P*$*D"*Q M3IDZ^V'MNTWS9HWMW>+#FWFS_P"L7"MJI6$$3,TE)=0LS2E.*E`3RD8YDW[O M*[T.XSLGMJA\WXB3RFY+;;"A[(20K2L"16M4@"?+C`NXI[>=5@+UD*?[D%G7 M>9(>(+SXMK[E_(E)3MQ%@357L;#(4!B/*ZV2'BCOJ30%!\BW6*/JE4#;I>-R M=U:]='1TG:!MHV600>FPAXI.02I'406@@9J()YF<(]K[0K;J'KAOY?7JI:I* M=4W(G,S""I9&4AA!V1N><@)5&)Q1QWF+!C;%@/&E8@<28LM./YK(,R=R+55T MM7X`.,-?D4A<,5/,%RJ"`.@'8RZI^H`15[8MC-:JZ[OT/WM22ZJH<#B*=)S2 M%$OD$_P2]4HL6VIK$T2;=8AT[4A80&TJ!5XJD6M6/,DP3.)^*>0I^,5Q_E&6 MLL["RDZ6?1P16$J1]N),"@F#(F<I(<'%`#B<)91<^(\:8PN7-O%>.Z;&4F7A<38[O+C*L1C-F5O0JLT.FT:5JI MOK"V5%>ZS2-A<$%^Y46P<''P][HZIE79<6WPZJA(]X?<3NZ);TE$Y>I2I"?V1TU$PZ@_6&4#U=(MHO MUVL50*RUON,5:?E`X*'S5I]E0/B)^,615T%)7M%NJ;2M)X_*'H,`39GG&/AD MO-U]Q8TJU,$$[-_`TV00R+R+NK%C)16.88#JBB1L)V>Z2?49!41 MW&2ON[;_`+G/_P!5\J9G,-I\K2#X)'M$\U$QKT-GH+9/W5`2LYG,GZQQ_<(I M:%R#RBYOF<8JXM8_'!6#%%B,;A9FS]V!I)(Y2IN5L@9)*W0?33LZ/4;W3%%` MQP$0.!R#N"R1I\QQ,20GP$.>X@\0*'Q(H2U?@%AL-RL!FKV\WETV(U=SSYL0 MP-V;%H4ZONNOQOF'!LU`YQZCF44,=0PB&"E%1QC,"0@NM?(^Q-$$31!'PP=0 M;:^$3PX0''/&!4R5<,+<1$F( M]B@9HWWGZ?RI?5J4G@5Y%?I(E/G*%=SV>.>//M5W"<<*=(8/P>Z5<,EKU)R" MD(ZFF@=:2WMUS!`STY5VZX=;.`04$@CTJ.#AKPD$GS&?A&Z)Y#`1?V!.T9A> MCJ(6+-DR_P`UVTRIG;J.=`YAZ*F\5(!E!6CDW!YBQJ$7$3>:]=`FK^D@'CO] M+AX81]"1QAK<'`0=9BF4%78>+@H6.1*W81,.P;1L:S0('21)JR:)I-T"%`/0 M4H:\R23,QE'KZ((FB")H@B:((_-55-!-1990B221#JJJJ&`B:::91.C\T,LR'+#D.R5E<6-'\E"\=,-RP&4A!ID:[4:-;Y9 MV)Q!)U]J'+<7R#82[+@=,ZPG1*B364Y"0SXQC(G.&ML6+2-9MF$>U;,6+)!) MJS9,D$FK-FU0(5)!JT;($31;MT$B@4A"%`I2@``&VL8RCMZ((FB")H@B:((F MB")H@CIR)&:C!ZG(F0+'G:.2/QQH@B:((FB")H@B:((FB"/_V3\_ ` end